Literature DB >> 20650988

Predictive accuracy of patient-reported exacerbation frequency in COPD.

J K Quint1, G C Donaldson, J R Hurst, J J P Goldring, T R Seemungal, J A Wedzicha.   

Abstract

Chronic obstructive pulmonary disease (COPD) exacerbation frequency is important for clinical risk assessment and trial recruitment. In order to accurately establish exacerbation frequency, patients need to be followed for 1 yr, although this is not always practical. 1) Patient recall of exacerbation number during the year prior to recruitment to the London COPD cohort was compared with the number of exacerbations recorded on diary cards during the subsequent year; and 2) patient recall of their exacerbation number after 1 yr of follow-up was compared with documented exacerbations over the same year. A total of 267 patients (forced expiratory volume in 1 s 1.14 L) recorded worsening of respiratory symptoms on daily diary cards for 1 yr. Exacerbations were defined according to previously validated criteria. There was no difference between the exacerbation number recalled by patients prior to recruitment and the number detected during the first year (median 2.0 (interquartile range 1.0-4.0) and 2.0 (1.0-4.0); expected agreement 76.4%; agreement 84.6%; κ = 0.3469). There was no difference between the number of exacerbations remembered by patients and the number recorded on diary cards over the same 1-yr period (2.0 (1.0-4.0) for both groups; expected agreement 74.9%; actual agreement 93.3%; κ = 0.6146). Patients remember the number of exacerbations they have in a year. Accuracy is increased when comparing the same 1-yr period. Patient recall is sufficiently robust for stratification into frequent and infrequent exacerbator groups for subsequent years.

Entities:  

Mesh:

Year:  2010        PMID: 20650988     DOI: 10.1183/09031936.00035909

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  26 in total

1.  Racial differences in quality of life in patients with COPD.

Authors:  MeiLan K Han; Douglas Curran-Everett; Mark T Dransfield; Gerard J Criner; Lening Zhang; James R Murphy; Nadia N Hansel; Dawn L DeMeo; Nicola A Hanania; Elizabeth A Regan; Barry J Make; Fernando J Martinez; Gloria E Westney; Marilyn G Foreman
Journal:  Chest       Date:  2011-06-02       Impact factor: 9.410

2.  Effect of Tiotropium on Outcomes in Patients With COPD, Categorized Using the New GOLD Grading System: Results of the UPLIFT® Randomized Controlled Trial.

Authors:  David M G Halpin; Donald P Tashkin; Bartolome R Celli; Inge Leimer; Norbert Metzdorf; Marc Decramer
Journal:  Chronic Obstr Pulm Dis       Date:  2015-06-23

3.  [Spanish COPD Guidelines (GesEPOC): Pharmacological treatment of stable COPD].

Authors:  Marc Miravitlles; Juan José Soler-Cataluña; Myriam Calle; Jesús Molina; Pere Almagro; José Antonio Quintano; Juan Antonio Riesco; Juan Antonio Trigueros; Pascual Piñera; Adolfo Simón; José Luis López-Campos; Joan B Soriano; Julio Ancochea
Journal:  Aten Primaria       Date:  2012-06-15       Impact factor: 1.137

4.  Lower health literacy is associated with poorer health status and outcomes in chronic obstructive pulmonary disease.

Authors:  Theodore A Omachi; Urmimala Sarkar; Edward H Yelin; Paul D Blanc; Patricia P Katz
Journal:  J Gen Intern Med       Date:  2012-08-14       Impact factor: 5.128

5.  Effect of Theophylline as Adjunct to Inhaled Corticosteroids on Exacerbations in Patients With COPD: A Randomized Clinical Trial.

Authors:  Graham Devereux; Seonaidh Cotton; Shona Fielding; Nicola McMeekin; Peter J Barnes; Andrew Briggs; Graham Burns; Rekha Chaudhuri; Henry Chrystyn; Lisa Davies; Anthony De Soyza; Simon Gompertz; John Haughney; Karen Innes; Joanna Kaniewska; Amanda Lee; Alyn Morice; John Norrie; Anita Sullivan; Andrew Wilson; David Price
Journal:  JAMA       Date:  2018-10-16       Impact factor: 56.272

6.  25-hydroxyvitamin D deficiency, exacerbation frequency and human rhinovirus exacerbations in chronic obstructive pulmonary disease.

Authors:  Jennifer K Quint; Gavin C Donaldson; Nancy Wassef; John R Hurst; Michael Thomas; Jadwiga A Wedzicha
Journal:  BMC Pulm Med       Date:  2012-06-22       Impact factor: 3.317

7.  Use of low-dose oral theophylline as an adjunct to inhaled corticosteroids in preventing exacerbations of chronic obstructive pulmonary disease: study protocol for a randomised controlled trial.

Authors:  Graham Devereux; Seonaidh Cotton; Peter Barnes; Andrew Briggs; Graham Burns; Rekha Chaudhuri; Henry Chrystyn; Lisa Davies; Anthony De Soyza; Shona Fielding; Simon Gompertz; John Haughney; Amanda J Lee; Kirsty McCormack; Gladys McPherson; Alyn Morice; John Norrie; Anita Sullivan; Andrew Wilson; David Price
Journal:  Trials       Date:  2015-06-10       Impact factor: 2.279

8.  A comparison of three multidimensional indices of COPD severity as predictors of future exacerbations.

Authors:  Takashi Motegi; Rupert C Jones; Takeo Ishii; Kumiko Hattori; Yuji Kusunoki; Ryuko Furutate; Kouich Yamada; Akihiko Gemma; Kozui Kida
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2013-05-31

Review 9.  The role of bronchodilator treatment in the prevention of exacerbations of COPD.

Authors:  Jadwiga A Wedzicha; Marc Decramer; Terence A R Seemungal
Journal:  Eur Respir J       Date:  2012-07-26       Impact factor: 16.671

10.  Factors associated with change in exacerbation frequency in COPD.

Authors:  Gavin C Donaldson; Hanna Müllerova; Nicholas Locantore; John R Hurst; Peter M A Calverley; Jorgen Vestbo; Antonio Anzueto; Jadwiga A Wedzicha
Journal:  Respir Res       Date:  2013-07-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.